Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 17/20 | 1.00 |
| ▸ | NR1H3 | Q13133 | 16/20 | 1.00 |
| ▸ | PPARA | Q07869 | 15/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 14/20 | 1.00 |
| ▸ | PPARG | P37231 | 12/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29816268 | 1.00 | PPARD (1.00) | PPARDNR1H3PPARANR1H2PPARG | |
| SCHEMBL7044517 | 0.92 | PPARD (0.86) | PPARDNR1H3PPARANR1H2PPARG | |
| SCHEMBL23139545 | 0.92 | PPARD (0.84) | PPARDNR1H3PPARANR1H2PPARG | |
| SCHEMBL7044450 | 0.91 | NR1H3 (0.84) | PPARDNR1H3PPARANR1H2PPARG | |
| SCHEMBL7038966 | 0.89 | PPARD (0.92) | PPARDNR1H3PPARANR1H2PPARG | |
| SCHEMBL5535084 | 0.89 | PPARD (0.83) | PPARDNR1H3PPARANR1H2PPARG | |
| L-165461 SCHEMBL6753428 | 0.88 | PPARD (1.00) | PPARDNR1H3PPARANR1H2PPARG | |
| SCHEMBL7040820 | 0.88 | PPARG (1.00) | PPARDNR1H3PPARANR1H2PPARG | |
| SCHEMBL7041413 | 0.87 | PPARD (0.81) | PPARDNR1H3PPARANR1H2PPARG | |
| SCHEMBL7044955 | 0.87 | PPARD (0.87) | PPARDNR1H3PPARANR1H2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0882029-B1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO INC (US) | 2003-04-02 | — | — | EP | claimed |
| US-6090836-A | DIETETICS; ADJUSTMENT OF TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | claimed |
| EP-0882029-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | claimed |
| WO-1997028137-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | claimed |
| CN-114195672-A | Amide prodrugs of small molecule nuclear receptor modulators | 俄勒冈健康科学大学 | 2022-03-18 | — | — | CN | disclosed |
| CN-111801013-B | Amide prodrugs of small molecule nuclear receptor modulators | 俄勒冈健康科学大学 | 2021-12-24 | — | — | CN | disclosed |
| US-20210087137-A1 | AMIDE PRODRUGS OF SMALL MOLECULE NUCLEAR RECEPTOR MODULATORS | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2021-03-25 | — | — | US | disclosed |
| CN-111801013-A | Amide prodrugs of small molecule nuclear receptor modulators | 俄勒冈健康科学大学 | 2020-10-20 | — | — | CN | disclosed |
| WO-2017044551-A1 | PPAR-ALPHA AGONISTS FOR TREATING MITOCHONDRIAL DISEASES | MITOBRIDGE, INC. (US) | 2017-03-16 | — | — | WO | disclosed |
| EP-2155187-B1 | METHOD OF TREATMENT USING FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | UNIV CASE WESTERN RESERVE (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2013056232-A2 | RXR AGONISTS COMPOUNDS AND METHODS | CASE WESTERN RESERVE UNIVERSITY (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20020042441-A1 | N-substituted indoles useful in the treatment of diabetes | MERCK SHARP & DOHME CORP. | 2002-04-11 | — | — | US | disclosed |
| WO-2002026729-A2 | BENZOPYRANCARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF DIABETES AND LIPID DISORDERS | MERCK & CO., INC. (US) | 2002-04-04 | — | — | WO | disclosed |
| WO-2002015845-A2 | ANTI-HYPERCHOLESTEROLEMIC DRUG COMBINATION | MERCK & CO., INC. (US) | 2002-02-28 | — | — | WO | disclosed |
| WO-2002008188-A1 | N-SUBSTITUTED INDOLES USEFUL IN THE TREATMENT OF DIABETES | MERCK & CO., INC. (US) | 2002-01-31 | — | — | WO | disclosed |
| WO-2001060807-A1 | ARYLOXYACETIC ACIDS FOR DIABETES AND LIPID DISORDERS | MERCK & CO. INC. (US) | 2001-08-23 | — | — | WO | disclosed |
| US-6090836-A | DIETETICS; ADJUSTMENT OF TRIGLYCERIDE CONCENTRATION | MERCK & CO., INC. (US) | 2000-07-18 | — | — | US | disclosed |
| EP-0882029-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | Merck & Co., Inc. (US) | 1998-12-09 | — | — | EP | disclosed |
| WO-1997028137-A1 | HETEROCYCLIC DERIVATIVES AS ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. (US) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210087137-A1 | AMIDE PRODRUGS OF SMALL MOLECULE NUCLEAR RECEPTOR MODULATORS | NR1I2, NR1D2, NR1I3 | PPARD 81/4885NR1H3 9/4885PPARA 103/4885 |
| US-20020042441-A1 | N-substituted indoles useful in the treatment of diabetes | GPR119, PPARA, INSR | PPARD 5/4885NR1H3 52/4885PPARA 2/4885 |
| US-20140235676-A1 | RXR AGONIST COMPOUNDS AND METHODS | RXRA, RXRB, RXRG | PPARD 46/4885NR1H3 21/4885PPARA 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.